ReviewJournal of applied genetics2026
Unravelling obesity: from leptin to glucagon-like peptide-1 receptor agonists.
Review in Journal of applied genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global obesity epidemic involves a multifaceted interplay between genetics, environment, and the interactions between them. The discovery of leptin in 1994 changed our understanding of body weight regulation and triggered extensive genetic studies into monogenic and polygenic obesity. Despite initial therapeutic hopes, leptin's efficacy in obesity was limited by leptin resistance. However, glucagon-like peptide-1, an incretin hormone, has become an important tool for managing obesity. Glucagon-like peptide-1 receptor agonists aid in weight loss and glycemic control while also providing metabolic and cardiovascular benefits. This article presents the shift from leptin biology to the therapeutic application of glucagon-like peptide-1 receptor analogs, focusing on their unique mechanisms, gene polymorphisms, and the hormonal interactions that regulate energy homeostasis. It outlines the shift from leptin-based theories to therapies focused on glucagon-like peptide-1 as we have gained understanding of the gut-brain-adipose axis, paving the way for targeted therapies in obesity management.
Indexed as
Identifiers
42298277What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.